Mayne Pharma Group Limited (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Limited (ASX: MYX)
Latest News
Share Market News
ALL ORDINARIES finishes higher Friday: 8 ASX shares you missed
Share Market News
Why Mayne Pharma shares tanked on its AGM
Share Fallers
Why Gentrack, Mayne Pharma, Metcash, & Regional Express are dropping lower
Share Market News
ASX 200 lunch update: Mayne Pharma, & Westpac lower, Pilbara Minerals higher
Healthcare Shares
Mayne Pharma share price on watch ahead of AGM update
Share Market News
Incitec's share price fights back despite broker downgrades
Healthcare Shares
ASX listed healthcare shares explained
Share Fallers
ALL ORDINARIES finishes higher Tuesday: 8 ASX shares you missed
Share Gainers
Why Clinuvel, HUB24, Mayne Pharma, & New Century shares charged higher today
Share Market News
ASX 200 lunch time report: ANZ & Mayne Pharma higher, Afterpay lower
Share Gainers
ALL ORDINARIES finishes higher Monday: 8 ASX shares you missed
Share Fallers
Why Altura Mining, Mayne Pharma, Nick Scali, & Speedcast shares tumbled lower
Frequently Asked Questions
-
Mayne Pharma made a fully franked cash payment to shareholders in January 2023. Prior to that, the company’s last dividend payout was in 2011.
-
Mayne Pharma Group Ltd listed on the ASX on 29 June 2007.
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Limited
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company focused on commercialising branded and generic pharmaceutical products. Its South Australian manufacturing base produces a portfolio of oral and topical products including tablets, powders, capsules, liquids, and creams.
Mayne Pharma performs limited research and development, typically acquiring off-patent or tail-end pharmaceutical brands. The company also has a contract manufacturing segment and advertises its services in assisting other drug developers in getting their products to market. The Group earns more than 90% of its revenue from the US market.
